Industries > Pharma > Global Asthma & COPD Therapies Market 2017-2027

Global Asthma & COPD Therapies Market 2017-2027

Bronchodilator Monotherapy, Anticholinergics, Short-acting Beta-Agonists (SABAs), Long-acting Beta-Agonists (LABAs), Long-acting Muscarinic Antagonists (LAMAs), Anti-Inflammatory Drugs, Corticosteroids, Anti-Leukotrienes, Monoclonal Antibodies, Combination Drugs

PUBLISHED: 06 September 2017
PAGES: 300
PRODUCT CODE: PHA0234

Clear
WOOCS 2.2.1
SKU: PHA0234 Categories: , , Tags: ,

The global asthma & COPD therapies market was valued at $32.9bn in 2016 and is projected to grow at a CAGR of 5.6% in the first half of the forecast period. The Anti-inflammatory Drugs submarket will be the fastest growing submarket in the first half of the forecast period. This submarket is estimated to grow at a CAGR of 7.6%.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 300-page report you will receive 113 tables and 130 figures – all unavailable elsewhere.

The 300-page report provides clear detailed insight into the global asthma & COPD therapies market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope
Global Asthma & COPD Therapies Market forecasts from 2017-2027, further broken down into:
Global Asthma Therapies Market forecasts
Global COPD Therapies Market forecasts

Revenue forecasts of the three main drug classes of the global asthma & COPD therapies market:
– Bronchodilators monotherapy
– Anti-inflammatory drugs
– Combination drugs

Revenue forecast for the Bronchodilators monotherapy market by Type and revenue forecast of the leading drugs:
Short-acting beta2-agonists (SABAs): Ventolin, ProAir, Proventil, Xopenex
Long-acting beta2-agonists (LABAs): Brovana, Foradil, Arcapta/Onbrez, Serevent,
Anticholinergics: Spiriva, Atrovent, Eklira/Tudorza/Bretaris

Revenue forecast for the Anti-inflammatory drugs market by Type and revenue forecast of the leading drugs:
Corticosteroids: Pulmicort, Flixotide/Flovent, QVAR, Asmanex
Anti-leukotrienes: Singulair
Monoclonal antibodies (mAbs): Xolair, Cinquil/Cinquair, Nucala, Benralizumab, Lebrikizumab, Dupilumab

Revenue forecast for the Combination drugs market and the leading drugs:
– Advair/Seretide, Symbicort, Combivent, Dulera, Relvar/Breo

• This report provides individual revenue forecasts from 2017-2027 for these regional and national markets:
– The US
– Japan
– EU5: Germany, France, UK, Italy, Spain
– BRIC: Brazil, Russia, India, China
– Mexico
– Other Countries

Global Asthma & COPD Therapies Market 2017-2027

• This report discusses the leading companies in the global asthma & COPD therapies market:
– GSK
– Boehringer Ingelheim
– AstraZeneca
– Novartis
– Merck
– Roche
– Teva

• This report discusses drugs currently in clinical development for treating asthma and COPD.

• This report discusses the SWOT analysis as well as porter’s five forces analysis of the global asthma & COPD therapies market.

Visiongain’s study is intended for anyone requiring commercial analyses for the global asthma & COPD therapies market. You find data, trends and predictions.

Buy our report today Global Asthma & COPD Therapies Market 2017-2027:
Bronchodilator Monotherapy, Anticholinergics, Short-acting Beta-Agonists (SABAs), Long-acting Beta-Agonists (LABAs), Long-acting Muscarinic Antagonists (LAMAs), Anti-Inflammatory Drugs, Corticosteroids, Anti-Leukotrienes, Monoclonal Antibodies, Combination Drugs
.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Global Asthma & COPD Therapies Market 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Global Asthma & COPD Therapies Market 2017-2027


Latest Pharma news

Visiongain Publishes Clinical Trial Supplies Market Report 2021-2031

Deviating from protocols raises the danger of missing or delaying data collection from current investigations. This highlights the growing importance of digital medicine, which is being aided by advancements in cloud, mobile, and IoT technology.

11 October 2021

READ

Visiongain Publishes Drug Discovery Informatics Market Report 2021-2031

High performance HPC and supercomputing technology have evolved substantially in China in the last decades, leading to extraordinary accomplishments. HPC-based and combined pharmaceutical chemical and computational biology computational discovery and design has become a significant technique in drug research and development and is sponsored financially by the Chinese government.

07 October 2021

READ

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2021-2031

Many health-care organizations are seeing organic growth at levels that their supply networks were never designed to handle. Others are frantically attempting to integrate diverse technology and procedures as part of a consolidation effort.

06 October 2021

READ

Visiongain Publishes Meningococcal Vaccines Market Report 2021-2031

Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations is expected to drive the global meningococcal vaccines market

05 October 2021

READ

Categories